MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijcard.2026.134588

Медицинская библиотека · International journal of cardiology · 2026

GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study.

Mahmoud Ahmed K, Sheashaa Hesham, Killian Michael, Awad Kamal, Ibrahim Ramzi, Mahmoud Alaa, Farina Juan, Abdelnabi Mahmoud, Kamel Ibrahim, Horn Benjamin, Simper David, Lester Steven J, Ayoub Chadi, Arsanjani Reza

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Elevated lipoprotein(a) [Lp(a)] is a well-established, genetically mediated risk factor for atherosclerotic cardiovascular disease (ASCVD), yet effective therapies targeting Lp(a) remain limited. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide cardiometabolic benefits in high-risk populations, but their impact among patients with elevated Lp(a) levels is not well defined.

METHODS

We conducted a retrospective cohort study to evaluate cardiovascular outcomes associated with GLP-1RA therapy in adults with Lp(a) >50 mg/dL and comorbid obesity or type 2 diabetes. Patients were categorized into GLP-1RA users versus non-users and matched 1:1 using propensity scores based on demographics, cardiovascular risk factors, and baseline comorbidities. The primary outcome was all-cause mortality; secondary outcomes included major adverse cardiovascular events (MACE: myocardial infarction, ischemic stroke, and coronary revascularization). Hazard ratios (HR) with 95% confidence intervals (CI) were estimated using Cox proportional hazards models.

RESULTS

Among 24,185 eligible patients, 3791 received a GLP-1RA. After matching, 3310 patients remained in each cohort with balanced baseline characteristics. Over a median follow-up of approximately two years, GLP-1RA use was associated with significantly lower all-cause mortality (HR 0.66, 95% CI 0.48-0.90) and reduced MACE (HR 0.68, 95% CI 0.60-0.76). Individual components, including myocardial infarction, ischemic stroke, and cardiovascular death, were also significantly decreased among GLP-1RA users.

CONCLUSION

In patients with elevated Lp(a), GLP-1RA therapy was associated with substantial reductions in mortality and cardiovascular events. These findings suggest potential cardioprotective effects of GLP-1RAs in a high-risk population with limited therapeutic options and support further prospective evaluation.

Для цитирования: Mahmoud Ahmed K, Sheashaa Hesham, Killian Michael, Awad Kamal, Ibrahim Ramzi, Mahmoud Alaa, Farina Juan, Abdelnabi Mahmoud, Kamel Ibrahim, Horn Benjamin, Simper David, Lester Steven J, Ayoub Chadi, Arsanjani Reza. GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study.. International journal of cardiology. 2026. DOI: 10.1016/j.ijcard.2026.134588.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.